Proteome SciencesPMSNF 5-Year ROIIC % is -51.48 as of Dec. 2025. The stock has 6 warning signs investors should review. Among 189 Medical Diagnostics & Research companies, Proteome Sciences ranks worse than 78.84% on this metric.
5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year.
Proteome Sciences's 5-Year ROIIC % for the quarter that ended in Dec. 2025 was -51.48%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Proteome Sciences's 5-Year ROIIC % or its related term are showing as below:
PMSNF's 5-Year ROIIC % is ranked worse than 78.84% of 189
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.62
vs PMSNF: -51.48
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Proteome Sciences 5-Year ROIIC % Related Terms
Proteome Sciences 5-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Proteome Sciences's 5-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PMSNF vs TMO, DHR, IDXX: 5-Year ROIIC % Comparison
For the Diagnostics & Research subindustry, Proteome Sciences's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Proteome Sciences 5-Year ROIIC % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Proteome Sciences's 5-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Proteome Sciences's 5-Year ROIIC % falls into.
Proteome Sciences's 5-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
5-Year ROIIC %
=
5-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
5-Year Incremental Invested Capital**
=
( -3.0418587 (Dec. 2025) - 0.738 (Dec. 2020) )
/
( 28.543 (Dec. 2025) - 21.291 (Dec. 2020) )
=
-3.7798587
/
7.252
=
-52.12%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Proteome Sciences (PMSNF) has a 5-Year ROIIC % of -51.48 as of Dec. 2025. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on Proteome Sciences and its competitors. According to the industry distribution chart, Proteome Sciences ranks #149 out of 189 companies in the Medical Diagnostics & Research industry, placing it in the top 78.8%.
Is Proteome Sciences' 5-Year ROIIC % too high?
Proteome Sciences' current 5-Year ROIIC % is -51.48. Based on the distribution chart, Proteome Sciences ranks #149 out of 189 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Proteome Sciences' 5-Year ROIIC % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Proteome Sciences ranks #149 out of 189 companies for 5-Year ROIIC %. This places Proteome Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year ROIIC % for a Medical Diagnostics & Research company?
A good 5-Year ROIIC % depends on the Medical Diagnostics & Research industry context. However, 5-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year ROIIC % mean?
A high 5-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on Proteome Sciences and its competitors. Proteome Sciences's current 5-Year ROIIC % is -51.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Proteome Sciences stock overvalued right now?
Proteome Sciences (PMSNF) has a current 5-Year ROIIC % of -51.48. The stock's GF Value™ is $0.03, compared to a current price of $0.02 — trading 17.5% below its estimated fair value. The current 5-Year ROIIC % is -51.48. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year ROIIC % calculated?
5-Year ROIIC % is calculated from a company's financial statements. For Proteome Sciences (PMSNF), the current 5-Year ROIIC % is -51.48 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Proteome Sciences PLC is engaged in protein biomarker research and development. The company is a provider of contract research services for the identification, validation and application of protein biomarkers. The company's only reportable segment is the sale of goods and biomarker services. The company generates maximum revenue from the TMT product and end customer sales-based royalties. Geographically, it has a presence in the United States, the United Kingdom, the European Union, and Others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PMSNF has been successfully added to your 